---
input_text: "A systematic review of clinical trials for gene therapies for beta-hemoglobinopathy
  around the world.BACKGROUND AIMS: Amidst the success of cell therapy for the treatment
  of onco-hematological diseases, the first recently Food and Drug Administration-approved
  gene therapy product for patients with transfusion-dependent beta-thalassemia (TDT)
  indicates the feasibility of gene therapy as curative for genetic hematologic disorders.
  This work analyzed the current-world scenario of clinical trials involving gene
  therapy for beta-hemoglobinopathies. METHODS: Eighteen trials for patients with
  sickle cell disease (SCD) and 24 for patients with TDT were analyzed. RESULTS: Most
  are phase 1 and 2 trials, funded by the industry and are currently recruiting volunteers.
  Treatment strategies for both diseases are fetal hemoglobin induction (52.4%); addition
  of wild-type or therapeutic beta-globin gene (38.1%) and correction of mutations
  (9,5%). Gene editing (52.4%) and gene addition (40.5%) are the two most used techniques.
  The United States and France are the countries with the greatest number of clinical
  trials centers for SCD, with 83.1% and 4.2%, respectively. The United States (41.1%),
  China (26%) and Italy (6.8%) lead TDT trials centers. CONCLUSIONS: Geographic trial
  concentration indicates the high costs of this technology, logistical issues and
  social challenges that need to be overcome for gene therapy to reach low- and middle-income
  countries where SCD and TDT are prevalent and where they most impact the patient's
  health."
raw_completion_output: |-
  primary_disease: beta-hemoglobinopathy
  medical_actions: gene therapy; fetal hemoglobin induction; addition of wild-type or therapeutic beta-globin gene; correction of mutations; gene editing; gene addition
  symptoms: transfusion-dependent
  chemicals: 
  action_annotation_relationships: gene therapy TREATS transfusion-dependent IN beta-hemoglobinopathy; fetal hemoglobin induction TREATS transfusion-dependent IN beta-hemoglobinopathy; addition of wild-type or therapeutic beta-globin gene TREATS transfusion-dependent IN beta-hemoglobinopathy; correction of mutations TREATS transfusion-dependent IN beta-hemoglobinopathy
prompt: |+
  From the text below, extract the following entities in the following format:

  subject_extension: <A chemical or drug mentioned in the relationship between the medical action and the symptom, for example, "analgesic agent therapy" has the aspect "analgesic">
  object_extension: <An optional term describing some specific aspect of the object, e.g. "analgesic agent therapy" has the aspect "analgesic">
  subject: <The medical action. For example: blood transfusion, radiation therapy, cardiac catheterization, pulse oximetry, otoscopy>
  predicate: <The relationship type between the medical action and the symptom, usually TREATS or PREVENTS.>
  object: <A sign or symptom associated with the disease and targeted by the medical action. For example, Low serum calcitriol, hypoplasia of the thymus, chronic cough, aortic stiffness, low pulse pressure>
  qualifier: <The primary disease the relationship is about, or specifically the disease the symptom is related to. For example, Beck-Fahrner syndrome, hereditary retinoblastoma, progeria, diabetes mellitus, infectious otitis media>
  subject_qualifier: <An optional qualifier or modifier for the subject of the statement, e.g. "high dose" or "intravenously administered">
  object_qualifier: <An optional qualifier or modifier for the object of the statement, e.g. "severe" or "with additional complications">


  Text:
  correction of mutations TREATS transfusion-dependent IN beta-hemoglobinopathy

  ===

extracted_object:
  primary_disease: beta-hemoglobinopathy
  medical_actions:
    - MAXO:0001001
    - fetal hemoglobin induction
    - addition of wild-type or therapeutic beta-globin gene
    - correction of mutations
    - gene editing
    - gene addition
  symptoms:
    - transfusion-dependent
  action_annotation_relationships:
    - subject: MAXO:0001001
      predicate: TREATS
      object: transfusion-dependent
      qualifier: beta-hemoglobinopathy
    - subject: fetal hemoglobin induction
      predicate: TREATS
      object: transfusion-dependent
      qualifier: beta-hemoglobinopathy
      subject_extension: fetal hemoglobin induction
    - subject: addition of wild-type or therapeutic
      predicate: TREATS
      object: transfusion-dependent
      qualifier: beta-hemoglobinopathy
      subject_extension: beta-globin gene
    - subject: correction
      predicate: TREATS
      object: transfusion-dependent
      qualifier: beta-hemoglobinopathy
      subject_extension: mutations
named_entities:
  - id: MONDO:0011382
    label: Sickle Cell Anemia
  - id: MONDO:0007374
    label: Sickle cell disease (SCD)
  - id: MAXO:0000747
    label: Allogeneic hematopoietic stem cell transplantation (HSCT)
  - id: MAXO:0000756
    label: blood transfusion
  - id: CHEBI:33281
    label: antibiotics
  - id: HP:0001944
    label: dehydration
  - id: HP:0007760
    label: Sickle Cell Disease (SCD) symptoms
  - id: HP:0012592
    label: Albuminuria
  - id: HP:0012622
    label: Chronic kidney disease
  - id: HP:0100543
    label: cognitive deficits
  - id: MAXO:0001001
    label: Gene therapy
  - id: HP:0002863
    label: myelodysplastic syndrome
  - id: HP:0004808
    label: acute myeloid leukemia
  - id: CHEBI:28901
    label: busulfan
  - id: HP:0010972
    label: Ineffective erythropoiesis
  - id: HP:0001878
    label: Hemolytic anemia
  - id: HP:0001903
    label: Anemia
  - id: CHEBI:35143
    label: Hemoglobin (HbS)
  - id: CHEBI:44423
    label: hydroxycarbamide
  - id: MONDO:0020380
    label: Sickle cell anemia (SCA)
  - id: MONDO:0002120
    label: Nasopharyngeal neuroendocrine carcinoma (NEC)
  - id: HP:0030828
    label: wheeze
  - id: HP:0012735
    label: cough
  - id: MONDO:0003664
    label: Haemolytic anaemias
  - id: HP:0032654
    label: Endothelial dysfunction
  - id: HP:0025464
    label: Oxidative stress
  - id: CHEBI:17627
    label: Haem
  - id: CHEBI:18248
    label: Iron
  - id: CHEBI:197439
    label: TNFalpha
  - id: MAXO:0000149
    label: haploidentical hematopoietic cell transplant (HCT)
  - id: MONDO:0005570
    label: Blood disorders
  - id: HP:0002617
    label: Vasculopathy
  - id: HP:0010885
    label: Bone infarctions
  - id: MONDO:0013517
    label: beta-thalassemia
  - id: HP:0001945
    label: fever
  - id: HP:0033050
    label: sore throat
  - id: HP:0002315
    label: headache
  - id: HP:0001394
    label: Cirrhosis
  - id: HP:0002204
    label: Pulmonary embolus
  - id: HP:0001297
    label: Stroke
  - id: HP:0031033
    label: Renal acidification defect
  - id: HP:0032632
    label: Renal papillary necrosis
  - id: HP:0000093
    label: Proteinuria
  - id: HP:0003774
    label: End-stage renal disease
  - id: HP:0012213
    label: Decreased glomerular filtration rate (GFR)
  - id: CHEBI:59163
    label: biomarkers
  - id: MAXO:0000915
    label: Standardized polysomnography (PSG)
  - id: HP:0002360
    label: Sleep disturbances
  - id: HP:0034312
    label: Nocturnal hypoxemia
  - id: CHEBI:35482
    label: opioid analgesics
  - id: MONDO:0005148
    label: type II diabetes
  - id: MAXO:0000058
    label: Pharmacotherapy
  - id: MAXO:0000457
    label: Pain management
  - id: CHEBI:18050
    label: L-glutamine
  - id: HP:0004421
    label: Elevated systolic blood pressure
  - id: HP:0030515
    label: Moderate visual impairment
  - id: HP:0000618
    label: Blindness
  - id: CHEBI:68579
    label: rivaroxaban
  - id: CHEBI:24261
    label: glucocorticoids
  - id: HP:0012532
    label: Chronic pain
  - id: CHEBI:6121
    label: Ketamine
  - id: MONDO:0010631
    label: Acute ischemic priapism (IP)
  - id: CHEBI:8093
    label: Phenylephrine
  - id: CHEBI:35480
    label: Analgesics
  - id: CHEBI:35705
    label: immunosuppressive agents
  - id: MAXO:0000503
    label: Mechanical ventilation
  - id: CHEBI:25555
    label: Nitrogen
  - id: HP:0001396
    label: Cholestasis
  - id: HP:0000083
    label: Kidney failure
  - id: CHEBI:50858
    label: Corticosteroids
  - id: CHEBI:9570
    label: thiotepa
  - id: CHEBI:4027
    label: cyclophosphamide
  - id: MAXO:0000494
    label: Blood pressure monitoring
  - id: HP:0003006
    label: lack of universal newborn screening (NBS)
  - id: MONDO:0002049
    label: Thrombocytopenia
  - id: MAXO:0001017
    label: vaccination
  - id: HP:0001873
    label: Thrombocytopenia
  - id: MONDO:0100096
    label: COVID-19
  - id: CHEBI:46195
    label: Acetaminophen
  - id: CHEBI:47381
    label: Diclofenac
  - id: MAXO:0000861
    label: Labor induction
  - id: HP:0100602
    label: Preeclampsia
  - id: CHEBI:16199
    label: Urea
  - id: CHEBI:16737
    label: Creatinine
  - id: MAXO:0000748
    label: Fecal microbiota transplantation (FMT)
  - id: CHEBI:17968
    label: Butyrate
  - id: CHEBI:31011
    label: Valerate
  - id: CHEBI:17272
    label: Propionate
  - id: MONDO:0020121
    label: muscular dystrophy
  - id: HP:0002664
    label: cancer
  - id: HP:0000819
    label: diabetes
  - id: MONDO:0004992
    label: cancer
  - id: MONDO:0005015
    label: diabetes
  - id: MAXO:0000610
    label: Enzyme-linked immunosorbent assay
  - id: HP:0007018
    label: Attention deficits
  - id: HP:0000848
    label: Increased plasma renin
  - id: CHEBI:48432
    label: Angiotensin II
  - id: CHEBI:4784
    label: Enalapril
  - id: HP:0100749
    label: Chest pain
  - id: HP:0002094
    label: Shortness of breath
  - id: HP:0000716
    label: Depression
  - id: HP:0001627
    label: Cardiac abnormalities
  - id: MONDO:0042491
    label: Contrast-induced nephropathy (CIN)
  - id: HP:0003259
    label: Elevated serum creatinine (SCr)
  - id: MONDO:0005399
    label: Venous thromboembolism (VTE)
  - id: MONDO:0054550
    label: Avascular Necrosis of the Femoral Head (AVNFH)
  - id: MAXO:0000004
    label: surgical intervention
  - id: HP:0012531
    label: pain
  - id: HP:0000969
    label: oedema
  - id: HP:0002140
    label: Ischemic cerebrovascular accidents
